GlassScriptPhysician profile
David R Clemmons
NPI 1649343401
$95,564.64
in general payments reported to CMS, 2019-2025
13 companies · $6,473 in 2025
The $6,473 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $9,005 · 2021: $16K · 2022: $9,578 · 2023: $19K · 2024: $13K · 2025: $6,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $805 · Food and Beverage: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,184.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,816.00 |
| Travel and Lodging | $805.07 |
| Food and Beverage | $448.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38,722.40 | 2019-2023 | Norditropin |
| Alexion Pharmaceuticals, INC. | $19,903.51 | 2024-2025 | |
| Pfizer INC. | $15,609.66 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $12,909.44 | 2023 | |
| Pfizer S.A.S. | $3,082.10 | 2021 | |
| Novo Nordisk Health Care Ag | $2,210.00 | 2021 | |
| Strongbridge US INC. | $1,800.00 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $400.00 | 2022 | |
| Horizon Therapeutics Plc | $300.00 | 2020 | |
| Allergan, INC. | $200.00 | 2020 | |
| Zoll Medical Corporation | $200.00 | 2020 | |
| Emd Millipore Corporation | $147.17 | 2019 | |
| Amryt Pharma Holdings LTD | $80.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Clemmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.